Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563687 | 0.70 | PSEN1 (0.47) | CYP3A4MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL22081220 | 0.62 | CCR3 (0.59) | ALDH1A1 | |
| SCHEMBL914593 | 0.61 | ACHE (0.50) | CYP3A4 | |
| SCHEMBL914594 | 0.61 | ACHE (0.50) | CYP3A4 | |
| SCHEMBL914591 | 0.61 | ACHE (0.50) | CYP3A4 | |
| SCHEMBL1200483 | 0.60 | GBA1 (0.42) | ALDH1A1 | |
| SCHEMBL2728492 | 0.60 | ALDH1A1 (0.38) | CYP3A4MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL11041884 | 0.60 | CYP1A2 (0.36) | CYP3A4MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL21917636 | 0.59 | SIGMAR1 (0.44) | CYP3A4 | |
| SCHEMBL21812103 | 0.59 | SIGMAR1 (0.44) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029537-B1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| US-9271959-B2 | Bicyclic tetrahydropyrrole compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-03-01 | — | — | US | disclosed |
| US-20130072456-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-21 | — | — | US | disclosed |
| US-8372990-B2 | Bicyclic tetrahydropyrrole compounds | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2013-02-12 | — | — | US | disclosed |
| US-20090318524-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-12-24 | — | — | US | disclosed |
| EP-2076493-A1 | PRODUCTION PROCESS FOR BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-08 | — | — | EP | disclosed |
| EP-2029537-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | Laboratorios del Dr. Esteve S.A. (ES) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007128459-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128457-A1 | PRODUCTION PROCESS FOR BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-15 | — | — | WO | disclosed |
| EP-1849772-A1 | Bicyclic tetrahydropyrrole compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849770-A1 | Production process for bicyclic tetrahydropyrrole compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072456-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | CYP11B2, CYP11B1, SDHA | CYP3A4 74/4885MEN1 1305/4885KMT2A 3710/4885 |
| US-20090318524-A1 | BICYCLIC TETRAHYDROPYRROLE COMPOUNDS | CYP11B2, CYP11B1, SDHA | CYP3A4 74/4885MEN1 1305/4885KMT2A 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.